Of note, ALK, NTRK, RET, and ROS1 targeting agents were found to have promising activity in the treatment of NSCLC-BM50, 51, 52 and might be considered as first-line therapy in lieu of radiotherapy or neurosurgery in selected patients.7 This evidence concerns the gene ALK and non-small cell lung carcinoma.